An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →
Novo Nordisk and Orbis Establish Partnership to Develop Oral Medications Worth Up to $1.4 Billion
Sep 18, 2026•about 2 hours ago
Contract Type
partnership
Financial ServicesVenture CapitalAngel Investment
Description
Novo Nordisk has entered a partnership with Orbis to develop oral alternatives to injectable medications for conditions like obesity and diabetes. The partnership is valued at up to $1.4 billion, including upfront and milestone payments as well as tiered royalties on future sales.
Company Information
Company
Orbis
About
Orbis is an investment management firm known for its global perspective and innovative approach to equity investment. The company focuses on delivering high-quality investment strategies and has built a reputation for strong stock-picking skills. With a dedicated local investment team, Orbis aims to outperform its competitors through rigorous analysis and strategic positioning. Their success is driven by a commitment to understanding complex themes affecting various markets.